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kg/m2, and an average CDAI or RI of 66.8 ± 42.4 and 3.6 ± 
3.1. No adverse events occurred during the 10-week training 
period. Health-related quality of life, reported as IBDQ total 
score, improved 19% in the intervention group and 8% in 
the control group. Scores for the IBDQ social sub-scale were 
significantly improved in the intervention group compared 
with controls (ΔIBDQ social = 6.27 ± 5.46 vs. 1.87 ± 4.76, p = 
0.023).  Conclusion: Patients suffering from moderately ac-
tive IBD are capable of performing symptom-free regular en-
durance exercise. Our data support the assumption that PA 
is feasible in IBD patients. PA may furthermore improve 
quality of life through improvements in social well-being, 
and may, therefore, be a useful adjunct to IBD therapy. 
 © 2015 S. Karger AG, Basel 
 Background 
 Gastrointestinal as well as extra-intestinal discomfort 
negatively affects the quality of life in patients with In-
flammatory Bowel Disease (Crohn‘s disease (CD) and ul-
cerative colitis (UC))  [1–3] . Besides somatic deteriora-
tion, the typical relapsing course of IBD often leads to 
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 Abstract 
 Background: Improving health-related quality of life is a pri-
mary target of therapy for patients with inflammatory bow-
el disease. Physical activity has been demonstrated to im-
prove health-related quality of life in several patient popula-
tions with chronic disease. There are very few studies 
investigating the effects of physical activity on health-relat-
ed quality of life in inflammatory bowel disease. The prima-
ry purpose of this study is to investigate the effects of 10 
weeks of moderate physical activity on health-related qual-
ity of life in patients with inflammatory bowel disease.  Meth-
ods: Thirty patients with mild to moderate IBD (Crohn‘s Dis-
ease Activity Index (CDAI) <220 or Rachmilewitz Index 
(RI) <11) were randomized 1: 1 to either supervised moder-
ate-intensity running thrice a week for 10 weeks or a control 
group who were not prescribed any exercise. Health-related 
quality of life, symptoms, and inflammation were assessed 
at baseline and after 10 weeks.  Results: Participants were 41 
± 14 years (73% female), had a body mass index of 22.8 ± 4.1 
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psychological distress, which evokes further impairment. 
Thus, patients suffering from IBD are frequently affected 
by depressive syndromes  [4, 5] . Despite multimodal med-
ical treatments, including immune-modulatory drugs 
and antibodies, there are no cures for IBD. Drug therapy 
aims at altering the course of disease, reducing symp-
toms, and improving health-related quality of life 
(HRQOL)  [6–9] . Therefore, strategies, including comple-
mentary pharmacological approaches and psychosocial 
support, are commonly used by patients with IBD  [10–
13] .
 Regular physical activity (PA) has become an impor-
tant complementary treatment strategy in several chron-
ic diseases, including coronary heart disease, metabolic 
syndrome, heart failure, breast cancer, and depression 
 [14–18] . However, PA as a therapeutic option for IBD has 
not been studied sufficiently, and little is known about the 
effect of regular PA on disease activity, inflammation, and 
quality of life  [19] . As in other chronic diseases, muscle 
function peak power and peak oxygen uptake are reduced 
in IBD patients  [20, 21] . Furthermore, to date, no nega-
tive side effects of moderate exercise on the physical con-
dition of IBD patients have been observed  [22] . These 
data suggest that physical activity may be a safe method 
that benefits patients with IBD. Therefore, the purpose of 
this study is to compare the effects of a physical activity 
program on changes in HRQOL in IBD patients.
 Patients and Methods 
 Patients 
 Patients were recruited during regular visits at the university 
hospital gastroenterology outpatient clinic between April and 
June 2013. In addition, patients were recruited during meetings of 
the  German Crohn’s Disease/ Ulcerative Colitis Association 
(Deutsche Morbus Crohn/Colitis ulcerosa Vereinigung, e.V.) self-
help groups. Patients who were 18 years or older were eligible to 
participate if either CD or UC was diagnosed at least one year be-
fore screening. Patients in remission or with mild active disease 
(Crohn‘s Disease Activity Index (CDAI) <220 points or Rachmile-
witz Index (RI) <11 points) were included. Exclusion criteria were 
high activity scores (CDAI  ≥ 220 or RI  ≥ 11) and/or contraindica-
tions to participation in regular PA (i.e., severe anemia, angina 
pectoris, severe ECG abnormalities). Patients with depression or 
psychosomatic disorders were not excluded. We furthermore ex-
cluded patients who participated in regular structured PA (>2 
hours/week).
 Explanatory material, including information about the study 
and possible health risks, was handed out. All participants gave 
written informed consent. The study was approved by the ethics 
committee of the Technical University of Munich (Protocol Num-
ber: 5709/13), and the trial is registered at  clinicaltrials.gov study 
register (NCT01834573).
 Assessment of HRQOL, IBD Activity, Physical Condition, and 
Medical History 
 All patients underwent physical examinations, 12-lead resting 
electrocardiography (EKG), routine laboratory tests (including 
analyses for inflammation markers), and fecal calprotectin mea-
surement before inclusion. Assessment of HRQOL was per-
formed using the German version of the IBDQ. The IBDQ is a 
validated test consisting of 32 questions covering four quality of 
life dimensions (bowel, systemic, social and emotional)  [23] . 
Questions can be responded to from 1 to 7 points, whereas high-
er values indicate better HRQOL. Groups of health-related qual-
ity of life were assessed directly before randomization and within 
14 days after the end of the intervention or control period. In-
flammatory bowel disease activity assessment was conducted us-
ing the CDAI or RI at the same time points. Both questionnaires 
assess subjective symptoms as well as objective measures (e.g., 
laboratory findings, body temperature). Scores  ≤ 150 and  ≤ 4 are 
regarded as disease remission in the CDAI and RI, respectively 
 [24, 25] . Values of >220 points have been used to define moder-
ately active disease  [26] . History of medication, alcohol, and to-
bacco use were assessed at the first visit before randomization 
(baseline values).
 Randomization 
 Consecutive patients were block-randomized 1: 1 to either in-
tervention or control groups after verifying inclusion and exclu-
sion criteria and receiving written informed consent. A computer-
generated randomization list was used, and participants were 
stratified according to the two IBD entities (CD or UC). Block 
sizes varied between four and six patients.
 Intervention 
 The exercise training was based on an established running pro-
gram that was developed in Munich for untrained people  [27] . The 
program is offered in three different forms depending on baseline 
Body Mass Index (BMI). Participants in the intervention group 
participated in the running program for BMI  ≤ 25. This consisted 
of supervised outdoor running at moderate intensity thrice per 
week for 10 weeks. Patients were advised to run or walk briskly in 
order to increase the heart ratio to the point of working up a sweat. 
‘Moderate intensity’ was furthermore defined by the condition 
that participants were still able to talk while running. Patients ran-
domized to the control group were encouraged to maintain their 
current lifestyle behaviors and to avoid PA exceeding two hours 
per week.
 Outcome Measures and Statistics 
 The primary aim of the trial was a comparison of study groups 
regarding change in total HRQOL from baseline to ten weeks after 
treatment initiation. Changes in HRQOL subscales were defined 
as secondary endpoints. Further secondary outcome measures 
were within-group changes of IBDQ scales. Absolute IBDQ im-
provement of at least 27 points has been determined to correlate 
with a clinical improvement (CDAI score decrease of 100 points) 
in the short term  [28] . We therefore chose an absolute IBDQ im-
provement of  ≥ 27 points as a secondary outcome measure. Finally, 
we performed within- and between-group comparisons of chang-
es in IBD activity scores (CDAI, RI) as well as body weight and 





















   
   
   
   
   
   
   
   
   
   
   


























 Statistical Analysis 
 As the study was planned as a feasibility study, sample size was 
not calculated a priori. Statistical analyses were performed using 
SAS version 9.3 and R version 3.3.1. A p value <0.05 was consid-
ered statistically significant.
 Quantitative data at baseline and at the end of follow-up were 
described by mean and standard deviation, if data followed a nor-
mal distribution, or by median, minimum, and maximum (crp, 
calprotectin, CDAI, and RI score). As no relevant deviations from 
the normal distribution were detected for calculated changes from 
baseline to end of follow-up for all quantities, these changes are 
summarized by means and standard deviations. Consequently, 
mean differences between groups were compared using the two-
sample t test, and within-group changes were assessed using paired 
 t -tests. For relevant measures, 95% confidence intervals are pre-
sented.
 Distributions of categorical data are presented by absolute fre-
quencies and percentages. The proportion of patients with a clini-
cally relevant increase in IBDQ of at least 27 points was compared 
between groups using Fisher’s exact test.
 Results 
 Subjects 
 A total of 132 patients were screened for participation, 
and 36 (26 female) were included ( table  1 ). There were 
three dropouts in the intervention group (two due to lack 
of motivation and one due to injury unrelated to the inter-
vention) and three in the control group (two did not attend 
follow-up, and one had incomplete HRQOL data;  fig. 1 ). 
All of the IG dropouts canceled participation before the 
beginning of the intervention. Therefore, complete data 
for per-protocol analysis was available in 30 cases ( fig. 1 ).
 Inflammatory Bowel Disease had been diagnosed on 
average 13.0 ± 8.8 years before study participation. No 
relevant differences were observed between groups with 
regard to patient characteristics, IBD-associated factors, 
or HRQOL at baseline ( table 1 ).
Table 1.  Baseline levels of patient characteristics, disease activity scores and HRQOL of 30 cases included
Patient characteristics All (n = 30) Intervention (n = 15) Control (n = 15)
Age, years 41.1±14.1 39.7±14.7 42.5±13.9
Gender, male, % 8 (27) 3 (20) 5 (33)
Disease duration, years 13.0±8.8 14.2±10.9 11.7±6.2
CD/UC, % 19/11 (63/37) 10/5 (67/33) 9/6 (60/40)
Disease activity
Crohn’s Disease Activity Index 66.8±42.4 68.8±44.1 64.7±43.2
Rachmilewitz Index 3.6±3.1 4.6±3.9 2.8±2.3
Patients taking IBD specific drugs, % 26 (87) 12 (80) 14 (93)
IBD specific drugs, %
Prednisolone (patients using P.) 5 (17) 4 (27) 1 (6)
Budesonide (patients using B.) 5 (17) 3 (20) 2 (13)
Mesalazine (patients using M.) 8 (27) 3 (20) 5 (33)
Azathioprine/6-MP (patients using A./6MP) 8 (27) 3 (20) 5 (33)
Methotrexate (patients using Mth.) 1 (3) 1 (7) 0
Infliximab (patients using Infl.) 4 (13) 2 (13) 2 (13)
Adalimumab (patients using Ad.) 3 (10) 1 (7) 2 (13)
Height, m 1.71±0.084 1.70±0.081 1.72±0.090
Weight, kg 67.0±15.5 61.0±9.7 72.9±18.2
Smoker, % 4 (13) 2 (13) 2 (13)
Alcohol consumption, % 12 (40) 8 (53) 4 (27)
IBDQ values (baseline)
IBDQ total score 162.1±33.0 156.5±35.0 167.7±31.1
IBDQ emotional score 57.7±15.0 54.4±14.7 61.0±15.1
IBDQ bowel score 54.4±8.7 54.2±9.0 54.6±8.8
IBDQ social score 27.4±7.7 25.2±7.5 29.7±7.5
IBDQ systemic score 22.6±6.1 22.7±7.2 22.4±5.0
Hemoglobin, g/dl 13.4±1.8 13.0±1.7 13.9±1.8
Leucocyte count, g/l 7.3±2.5 7.0±2.2 7.5±2.8
CRP, mg/dl 0.3 (<0.1 to 1.3) 0.2 (<0.1 to 1.3) 0.3 (<0.1 to 1.1)
Calprotectin, mg/kg 88 (<50 to 545) 68 (<30 to 227) 139 (<30 to 545)




















   
   
   
   
   
   
   
   
   
   
   


























 Feasibility of Training and Adverse Events 
 Fifteen patients completed the 10-week training pro-
gram. Patients performed a mean of 24 ± 4 out of 30 pos-
sible sessions. Out of a total of 89 missed sessions, only 
one absence was caused by IBD complaints. Reasons for 
not attending were lack of time (28/89, 31%), joint dis-
comfort not related to IBD (14/89, 16%), and other rea-
sons not related to IBD (e.g., hot weather or rain, absenc-
es due to holidays, other commitments; 47/89, 53%). All 
patients rated training as a success (yes/no question). 
Fourteen out of 15 participants in the intervention group 
said they would participate in a comparable program 
again. No serious or training-related adverse events oc-
curred during the intervention in IG or CG. Only one 
patient reported mild abdominal symptoms during and 
after training.
 Physical Activity in the Control Group 
 No participants in the control group exceeded two 
hours per week of PA. Twelve of 15 participants (80%) 
reported no PA at all, and three (20%) indicated that they 
had participated in weekly sports activities. Of these three, 
one participated in singles tennis; one practiced yoga; and 
one surfed or played volleyball.
 Health-Related Quality of Life 
 Improvements in total IBDQ score (ΔIBDQ total = 
28.3 ± 24.5 vs. 14.5 ± 16.1, p = 0.081), bowel sub-score 
(ΔIBDQ bowel = 6.8 ± 7.5 vs. 4.7 ± 5.2, p = 0.376), and emo-
tional (ΔIBDQ emotional = 11.1 ± 10.7 vs. 4.8 ± 7.1, p = 
0.068) and systemic sub-score (ΔIBDQ systemic = 4.1 ± 5.4 
vs. 3.2 ± 4.5, p = 0.611) did not differ significantly between 
the intervention and the control group ( table 2 ;  fig. 2 ). 
Participants in the intervention group improved their so-
cial well-being to a greater extent than did participants in 
the control group (ΔIBDQ social = 6.3 ± 5.5 vs. 1.9 ± 4.8, 
p = 0.026). Six patients (40%) in the intervention group 
and one (6.7%) in the control group (p = 0.080) improved 
total IBDQ score by at least 27 points, which was the sug-
gested threshold for clinical improvement.
 IBDQ Score Changes within Groups 
 IBDQ total scores were improved in IG compared with 
baseline (study end vs. start: 184.9 ± 20.9 vs. 156.5 ± 35.0, 
p = 0.001). Statistically significant increases were also ob-
served in all IBDQ dimensions, including emotional 
(65.5 ± 11.1 vs. 54.4 ± 14.7, p = 0.001), bowel (61.0 ± 5.2 vs. 
54.2 ± 9.0, p = 0.004), social (31.5 ± 5.6, vs. 25.2 ± 7.5, p = 
0.001), and systemic (26.9 ± 3.1 vs. 22.7 ± 7.2, p = 0.010).
 IBDQ total scores were also improved in controls 
compared to baseline values (study end vs. start: 182.2 ± 
26.6 vs. 167.7 ± 31.1, p = 0.004). Statistically significant 
increases were observed for the emotional (65.8 ± 14.6 vs. 
61.0 ± 15.1, p = 0.021), bowel (59.3 ± 7.1 vs. 54.6 ± 8.8, p = 
0.004), and systemic dimensions (25.6 ± 5.3 vs. 22.4 ± 5.0, 
p = 0.016). However, the IBDQ social dimension score 
did not significantly improve in controls from baseline to 
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 Disease Activity and Other Measurements 
 Change of disease activity scores, laboratory results, and 
body composition did not differ significantly between 
groups ( table 3 ). Regarding within-group comparison, leu-
cocyte counts showed a statistically significant decrease in 
IG (7.0 ± 2.2 vs. 5.6 ± 1.5, p = 0.016). We observed a change 
in calprotectin level in IG (mean increase of 185.0 ± 324.8 
mg/kg, p = 0.062), but the increase was not significantly 
different from zero. Differences in CG were similarly dis-
tributed (mean increase of 210.3 ± 621.3, p = 0.245). In-
flammatory parameters, IBD disease activity scores, and 
body composition measures are given in  table 3 .










mean IBDQ score 












Emotional IG 54.4±14.7 65.5±11.1 11.1±10.7 0.001 6.3 (–0.5 to 13.2) 0.068CG 61.0±15.1 65.8±14.6 4.8±7.1 0.021
Bowel IG 54.2±9.0 61.0±5.2 6.8±7.5 0.004 2.1 (–2.7 to 7.0) 0.376CG 54.6±8.8 59.3±7.1 4.7±5.2 0.004
Social IG 25.2±7.5 31.5±5.6 6.3±5.5 0.001 4.4 (0.6 to 8.2) 0.026*CG 29.7±7.5 31.5±5.1 1.9±4.8 0.151
Systemic IG 22.7±7.2 26.9±3.1 4.1±5.4 0.010 0.9 (–2.8 to 4.7) 0.611CG 22.4±5.0 25.6±5.3 3.2±4.5 0.016
Overall IG 156.5±35.0 184.9±20.9 28.3±24.5 0.001 13.8 (–1.8 to 29.4) 0.081CG 167.7±31.1 182.2±26.6 14.5±16.1 0.004











































































 Fig. 2. Comparison of intervention and 
control group regarding changes (follow-
up – baseline values) in IBDQ scores 





















   
   
   
   
   
   
   
   
   
   
   



























 Impact of Physical Exercise on HRQ OL
 We conducted a randomized controlled study in order 
to investigate the impact of 10 weeks of moderate inten-
sity physical activity on social and emotional aspects of 
health-related quality of life (HRQOL) in patients with 
mild inflammatory bowel disease (IBD). In the PA group, 
a mean increase in the total IBDQ score that was 13.8 
points higher than in the control group was observed. 
However, this difference was not statistically significant 
(95% CI: 1.8 to 29.4; p = 0.081). The mean change in the 
social well-being dimension of HRQOL was significantly 
higher for IG compared to CG.
 Our study therefore suggests a beneficial effect of reg-
ular exercise on social well-being in IBD patients. How-
ever, these insights derive from secondary outcome mea-
sures in a study with a small sample size. Results must 
therefore be interpreted with caution. Until now, there 
are very few randomized controlled trials available on the 
effect of PA on HRQOL in patients with IBD. In one un-
controlled trial, Loudon et al. conducted a three-month 
walking program in 12 patients with mildly active Crohn’s 
disease (CD). No adverse events were observed, and the 
patients improved HRQOL measured by total IBDQ 
scores  [29] . Ng and colleagues also investigated the effect 
of a three-month low-intensity walking program (30 min 
of walking, thrice a week) in CD patients with moderate 
disease, and although improvements in HRQOL were ob-
served, there were no differences between groups  [30] . In 
another study, 16 patients suffering from ulcerative colitis 
(UC) participated in six hours per week of stress manage-
ment training, moderate physical exercise, and behavior-
al techniques for a total of 10 weeks  [31] . In comparison 
to controls, participants showed a greater improvement 
in only the IBDQ dimension related to bowel discomfort. 
However, compared with our study, this study was not 
focused on physical activity, and the participants had 
some influence on their allocation assignments.
 The group-based PA applied in the current trial neces-
sarily included the formation of interpersonal contacts. 
By contrast, controls continued their previous lifestyle 
likely having fewer opportunities for social interaction. 
This fact might have influenced the observed improve-





















CDAI IG 51 (28 to 149) 41 (19–141) –11.3±38.0 0.372 –3.7 (–36.8 to 29.3) 0.814CG 67 (0–144) 50 (17–105) –7.6±30.0 0.471
RI IG 6 (0–9) 5 (0–6) –1.0±1.7 0.266 –0.2 (–2.6 to 2.3) 0.881CG 4 (0–5) 2 (0–5) –0.8±1.8 0.316
Weight, kg IG 61.0±9.7 62.0±9.0 1.0±1.9 0.063 1.0 (–0.3 to 2.4) 0.124CG 72.9±18.2 72.9±18.0 –0.1±1.7 0.882
BMI, kg/m2 IG 21.0±2.8 21.4±2.7 0.4±0.7 0.054 0.4 (0.0 to 0.9) 0.077CG 24.6±4.5 24.6±4.3 –0.0±0.6 0.751
Hemoglobin, 
g/dl
IG 13.0±1.7 13.2±1.2 0.3±1.5 0.535 0.4 (–0.5 to 1.2) 0.398CG 13.9±1.8 13.8±1.7 –0.1±0.6 0.463
Lc, g/l IG 7.0±2.2 5.6±1.5 –1.4±2.0 0.016 –0.7 (–2.3 to 0.9) 0.390CG 7.5±2.8 6.8±1.6 –0.7±2.3 0.250
CRP, mg/dl IG 0.2 (<0.1–1.3) 0.2 (<0.1–0.9) –0.1±0.3 0.520 0.0 (–0.3 to 0.2) 0.875CG 0.3 (<0.1–1.1) 0.2 (<0.1–1.4) 0.0±0.4 0.736
Calprotectin, 
mg/kg
IG 68.0 (<30–227.0) 141.0 (<30–1,069.0) 185.0±324.8 0.062 –25.3 (–433.6 to 383.0) 0.898CG 139.0 (<0.1–545.0) 229.0 (59.0–1,832.0) 210.3±621.3 0.245




















   
   
   
   
   
   
   
   
   
   
   


























ments of the social well-being component of HRQOL, as 
there is evidence in literature that social support is capa-
ble of influencing emotional IBDQ dimension scores in 
IBD  [32] . Interestingly, both IG and CG improved total 
HRQOL, with no statistically significant between-group 
differences. Patients in CG reported less than 2 hours of 
PA per week during the time of the intervention. Unfor-
tunately, we were not able to measure PA objectively (e.g. 
with accelerometers) and therefore do not know for sure 
how active they were. Other studies applying a similar 
design have observed large crossover effects, in that con-
trols became more active due to their inclusion in a study 
investigating exercise  [33] . Although crossover is likely to 
affect any study comparing the effects of exercise with 
non-exercise controls, further studies with larger samples 
and prescribed compensation for controls may help re-
solve some of these issues.
 Sports Are Feasible in IBD Patients Suffering from 
Moderately Active Disease 
 The implementation of regular PA for patients with 
IBD has gained recent support. There is no evidence of 
negative side effects of moderate PA in stable IBD pa-
tients  [22, 34, 35] . Furthermore, data suggest that espe-
cially extra-intestinal aspects of IBD (e.g. osteoporosis) 
are improved by PA  [36] . Traditionally, it was speculated 
that in patients with IBD with reduced exercise tolerance, 
regular exercise may actually do more harm than benefit 
 [19] . Currently, the performance of regular exercise is de-
sirable in most patient populations, including patients 
with IBD, and these concerns seem to have been unwar-
ranted  [37] . In agreement with current beliefs, we ob-
served that running exercise thrice a week for 10 weeks is 
feasible in IBD. No serious adverse events occurred dur-
ing the trial, and only one patient reported mild abdomi-
nal symptoms. Furthermore, we observed no relevant dif-
ference in change of inflammation markers between 
groups. In the IG, leucocyte counts decreased. This result 
is contrary to a recent finding from Ploeger et al., who 
found that leucocyte counts in pediatric IBD patients rose 
after the conduction of a bicycle ergometer training  [38] . 
In our trial follow-up, calprotectin concentration in IG 
was observed to be higher than at baseline, but the mean 
increase did not differ significantly from zero (185.0 ± 
324.8 mg/kg, p = 0.062). This fact may still be an indica-
tion of increased inflammation.
 It is currently unknown at which exercise volume and 
intensity IBD patients would benefit the most. In a mouse 
model of colitis, forced exercise resulted in an increased 
mortality rate, whereas voluntary training had a protective 
effect on inflammation and diarrhea  [39] . Regarding the 
relationship between exercise and course of disease in hu-
mans, our results suggest that moderate PA is feasible in 
stable IBD patients with mild activity, which is in accor-
dance with data collected from previous clinical trials  [29–
31, 38, 40] . Randomized controlled trials with adequate 
statistical power may be able to build on the current trial 
and definitively illustrate the effects of different volumes 
and intensities of PA on HRQOL and symptoms in IBD.
 Conclusion 
 Our data suggest that regular physical activity is a use-
ful complementary therapy tool that is capable of improv-
ing HRQOL and social well-being in patients suffering 
from mild active IBD. Patients with IBD seem to be able 
to perform running and walking without experiencing 
clinically meaningful adverse effects on intestinal and 
general health.
 Limitations 
 As no assumptions were made regarding the effect 
size, no sample size was calculated. Due to the small sam-
ple size, results must be interpreted with caution. Fur-
thermore, in order to highlight the actual effect of PA, we 
conducted per-protocol analysis and included patients 
with complete information regarding the primary end-
point measures. This method may have increased the 
likelihood for false-positive findings. Furthermore, con-
trols were not compensated, which might have led to bias. 
Finally, as we did not measure PA in controls objectively 
(e.g., with accelerometers), we do not know for sure how 
active they were. Crossover might have affected our re-
sults. Therefore, we are not able to explain why HRQOL 
improved also in controls.
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